Merck Sharp & Dohme Llc

This early-stage study tests two new vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus, such as infectious mononucleosis, certain cancers, and multiple sclerosis. About 250 healthy adults and teens will receive either the vaccine or a placeb…

This study tests a new vaccine called V118C to see if it is safe and works well in preventing pneumococcal infections in children. About 210 toddlers and infants will take part, comparing V118C to an existing vaccine. The main goal is to check for side effects and how the body re…

This study tests a new dengue vaccine called V181 in 12,000 healthy children aged 2 to 17. The goal is to see if the vaccine is safe, triggers a good immune response, and lowers the number of dengue cases. Participants will receive either the vaccine or a placebo and be monitored…

This study tests a new vaccine called V118E designed to protect against pneumococcal bacteria, which can cause pneumonia and other serious infections. Researchers want to see if it is safe and well-tolerated in 126 healthy adults. The vaccine is compared to an existing vaccine, P…

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than the current standard treatment (polatuzumab vedotin plus R-CHP) for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell ly…

This study tests a new targeted therapy (calderasib) plus immunotherapy (pembrolizumab) against standard chemo plus immunotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 675 participants will be enrolled to see if the new …

This study tests a new drug called patritumab deruxtecan in children whose liver cancer (hepatoblastoma) or muscle cancer (rhabdomyosarcoma) has returned or not responded to treatment. The drug works like a guided missile, attaching to a protein on cancer cells and delivering a p…

This study tests a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers, including colorectal, bile duct, liver, and stomach cancers that have spread. The main goals are to check the drug's safety and see if it can shrink or eliminate tumors. About 1…

This study tests whether a combination of two drugs, belzutifan and zanzalintinib, works better than the standard drug cabozantinib for people with advanced kidney cancer that has returned after prior treatment. About 904 participants will be randomly assigned to one of the two t…

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (durvalumab) helps people with a specific genetic subtype of advanced lung cancer (KRAS G12C) live longer without their cancer growing. About 310 adults who have finished chemotherapy and radi…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep the cancer from growing compared to standard chemotherapy. About 1,000 adults whose cancer has spread and …

This study tests an experimental drug called MK-8690 in 100 adults with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. Half get the drug, half get a placebo, and researchers check if more people on the …

This study tests adding new drugs to standard chemotherapy and pembrolizumab before surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. The main goals are to see if the cancer completely disappears from the removed tissue and how much of the t…

This study tests a drug called patritumab deruxtecan in people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The main goals are to check safety and see if the drug can shrink tumors. About 81 adults with this type of advanced breast cancer will…

This study is for people with advanced or metastatic solid tumors that have not responded to other treatments. It tests an experimental drug called MK-0472, given alone or with pembrolizumab or MK-1084. The main goals are to find safe doses and understand side effects. About 178 …

This study tests a new drug called MK-1084, alone or with cetuximab, in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to see if the tumors shrink or disappear and to check for side effects. About 150 adults whose cancer has worsene…

This study tests whether adding a targeted therapy (Sac-TMT) to standard chemotherapy and immunotherapy before surgery helps more people with high-risk, early-stage triple-negative or hormone-receptor-low breast cancer achieve a complete response (no cancer left in breast or lymp…

This study tests a new medicine called tulisokibart for people with active psoriatic arthritis (PsA), a condition causing joint pain and skin patches. About 140 adults will receive either the study drug or a placebo to see if it reduces symptoms like swelling and stiffness. The g…

This early-stage study tests a new experimental drug, MK-4646, in 28 people with HIV-1 who have never taken HIV medication. The main goals are to see if the drug is safe and tolerable, and to measure how much it lowers the amount of virus in the blood. Participants will take the …

This study is testing a new medicine called enlicitide decanoate in children and teens with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if the drug is safe, how the body processes it, and whether it lowers…

This early-stage study tests a new drug called MK-4716 in people with advanced or spreading solid tumors that have a specific genetic change (KRAS mutation). The main goal is to see if the drug is safe and tolerable when given alone or combined with another treatment. About 250 p…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy, in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink or stop the cancer. About 170…

This study tests new drug combinations, with or without the immunotherapy pembrolizumab and chemotherapy, in people with advanced esophageal cancer that has already been treated with PD-1/PD-L1 drugs. The goal is to find safer and more effective options for this hard-to-treat can…

This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or HR-low/HER2- breast cancer. About 372 participants will receive dif…

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced squamous non-small cell lung cancer live longer or keep their cancer from growing. About 180 adults who have not had prior tr…

This study tests a drug called sacituzumab tirumotecan (MK-2870), either by itself or combined with other cancer drugs, in people with advanced colorectal, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The main goals are to check the safety of…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has returned or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination or…

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

This study tests whether the experimental antiviral pill molnupiravir can prevent severe illness from COVID-19 in adults who are at high risk. About 3,000 non-hospitalized participants will receive either the pill or a placebo. The goal is to see if the drug reduces hospitalizati…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, and with another immunotherapy (durvalumab) in people with advanced small cell lung cancer that did not respond or stopped responding to prior treatment. About 262 participants …

This study tests an experimental drug called MK-2214 in 340 people with early Alzheimer's disease. The goal is to see if it can slow the buildup of a harmful protein called tau in the brain, which damages brain cells. Participants will receive either the drug or a placebo, and re…

This study tests whether adding the targeted drug sacituzumab tirumotecan to standard immunotherapy (pembrolizumab) and a blood-vessel blocker (bevacizumab) helps people with metastatic cervical cancer live longer or keep their cancer from growing. About 1,000 participants with P…

This early-stage study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goal is to check the drug's safety and find the highest dose people can tolerate. About 67 participants will receive the drug, and researchers will m…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (ET), a rare blood disorder causing too many platelets. Participants are adults whose current therapy (hydroxyurea) stopped working or caused side effect…

This study tests a new immunotherapy drug, MK-1045, in about 200 people with two types of non-Hodgkin lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) that have not responded to at least two prior treatments. The main goals are to check the drug's safety and see i…

This study tests if adding new drugs to a standard immunotherapy (pembrolizumab) can better shrink tumors in people with advanced lung cancer who haven't had treatment yet. About 450 adults with stage IV non-small cell lung cancer will receive different drug combinations. The goa…

This study looks at the long-term effects of belzutifan, a medicine that blocks a protein helping tumors grow. It is for people with advanced solid tumors or von Hippel-Lindau (VHL) disease who are already taking belzutifan in another trial. The main goal is to see how long parti…

This study tests whether adding the experimental drug MK-2870 to the immunotherapy pembrolizumab can prevent breast cancer from returning in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 1,530 participants will receiv…

This large study is testing different combinations of the drug pembrolizumab with chemotherapy and other experimental drugs for people with advanced non-small cell lung cancer. It aims to find which treatments work best for different tumor types. About 1065 participants will join…

This study tests an investigational drug called sotatercept in 42 children aged 1 to 18 who have pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to pump blood through the lungs. The main goals are to check the drug's safety and how it moves thro…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent non-small cell lung cancer from returning after surgery. About 868 adults with stage II to IIIB lung cancer who have had their tumor completely removed…

This study tests whether a personalized cancer vaccine (intismeran) given alone or with an immunotherapy drug (pembrolizumab) can prevent high-risk stage I non-small cell lung cancer from returning after complete surgical removal. About 876 adults whose tumors have certain high-r…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with advanced hormone receptor-positive, HER2-negative breast cancer that cannot be surgically removed or has spread. About 1,000 participants will be randomly assigned to…

This study tests two experimental drug combinations for people with advanced stomach, gastroesophageal junction, or esophagus cancer that has worsened after one prior treatment. About 210 participants will receive either a new antibody-drug combo plus standard chemo, or standard …

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already had two rounds of chemotherap…

This study looks at the long-term safety of the drug tulisokibart for people with moderate to severe Crohn's disease or ulcerative colitis. About 1,380 people who already took the drug in an earlier study can join. Researchers will track side effects and how well patients tolerat…

This study tests a new medicine called MK-1084 in people with advanced non-squamous non-small cell lung cancer that has a specific genetic change (KRAS G12C mutation). The goal is to see if the drug is safe and can shrink or stop the cancer. About 190 participants who have alread…

This study tests new antibody-drug conjugates (ADCs) for people with advanced squamous non-small cell lung cancer that didn't respond to standard immunotherapy or chemotherapy. ADCs are like guided missiles that deliver a powerful drug directly to cancer cells. The trial will com…

This study tests an oral drug called MK-1026 (nemtabrutinib) in about 490 people with certain blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. The main goals are to see how well the drug shrinks tumors and to check …

This study tests new drug combinations, including an antibody-drug conjugate, with the immunotherapy pembrolizumab (with or without chemotherapy) for people with advanced esophageal cancer that cannot be surgically removed. About 298 participants will join to see if these combina…

This study tests a drug called I-DXd in people with advanced esophageal cancer that has not responded to prior treatments. The drug works like a smart bomb, attaching to cancer cells and delivering a powerful treatment to destroy them. The main goal is to see how many participant…

This study tests a new medicine called MK-5684 for people with breast, ovarian, or endometrial cancer. The drug works by stopping the body from making certain hormones that can help cancers grow. Researchers will compare MK-5684 to standard treatments to see if it helps people li…

This study tests two new antibody-drug conjugates (ADCs) in people with advanced nonsquamous non-small cell lung cancer that has not responded to standard immunotherapy and chemotherapy. ADCs are like guided missiles that deliver a powerful drug directly to cancer cells. The tria…

This study tests whether adding the targeted drug MK-1084 to standard immunotherapy (pembrolizumab) can help prevent lung cancer from coming back after surgery. It involves 400 adults with a specific KRAS G12C mutation and stage IIA-IIIB non-small cell lung cancer. Participants w…

This study tests whether adding an experimental drug (V940) to standard immunotherapy (pembrolizumab) after surgery can keep non-small cell lung cancer from returning. It is for people whose tumors did not fully disappear with pre-surgery treatment. About 680 participants will re…

This study compares a new oral drug, nemtabrutinib, against two standard treatments (ibrutinib or acalabrutinib) for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 1,200 participants will be randomly assigned to receive nemtabrutinib or a …

This study tests an experimental drug called zilovertamab vedotin in children and young adults (ages 1 to <18) whose blood cancers (like B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, or Burkitt lymphoma) or solid tumors (neuroblastoma or Ewing sarcoma) have …

This study tests an experimental drug called MK-5684 (opevesostat), alone or with other treatments, in people with metastatic castration-resistant prostate cancer (mCRPC) that has stopped responding to standard hormone therapy. About 220 participants will join this early-phase tr…

This study looks at the long-term safety of the drug sotatercept for people with pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making breathing and activity hard. About 815 adults who completed earlier sotatercept studies will receive the dru…

This study tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemotherapy and immunotherapy can help people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive standard treatment plus either the extra dr…

This study tests a drug called Sac-TMT given directly into the bladder for people with intermediate-risk non-muscle invasive bladder cancer that has come back. The main goal is to find a safe dose and see if people can tolerate it. About 32 participants will take part in this ear…

This study is for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It tests new drug combinations, given alone or with pembrolizumab, to see if they are safe and can shrink tumors. About 48 adults will take part. The goal is to find bette…

This study tests whether adding new drugs, like patritumab deruxtecan, to standard immunotherapy (pembrolizumab) with or without chemotherapy can better treat advanced non-small cell lung cancer that has spread. About 90 people with untreated stage IV NSCLC will participate. The …

This study tests whether adding the targeted drugs MK-1084 and cetuximab to standard chemotherapy can help people with a specific type of advanced colorectal cancer (KRAS G12C mutation) live longer without their cancer growing. About 477 participants will receive either the new c…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This study is for people with advanced kidney cancer (clear cell type) that came back during or within two years of finishing initial immunotherapy. It tests new combinations of targeted and immune-based drugs to see if they are safe and can shrink tumors. The goal is to control …

This study tests a daily pill called belzutifan in people with advanced rare cancers, including pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumors, and tumors linked to von Hippel-Lindau disease. The goal is to see if the drug can shrink tumors and control the disea…

This study is testing the safety and how the body handles the antifungal drug posaconazole in infants under 2 years old who have a serious fungal infection. About 40 babies will receive the medicine through an IV or as a liquid to drink. The goal is to find the right dose for thi…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that got worse after one prior hormone treatment. About 1,314 participants will b…

This study is testing a drug called pembrolizumab in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphomas that have spread, come back, or not responded to treatment. The drug helps the immune system fight cancer. The goal is to see if it can shrin…

This study tests whether adding the experimental drug MK-1084 to standard immunotherapy (pembrolizumab) helps people with a specific genetic form of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, advanced…

This phase 3 study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing, compared to the current standard treatment (R-CHOP). About 1,046 par…

This study tests a new drug, MK-5684, against two standard treatments (abiraterone acetate or enzalutamide) in people with a type of advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. About 1310 participants will be randomly assig…

This study is for people with a type of advanced prostate cancer that has spread and stopped responding to hormone therapy. Researchers are testing a new drug called ifinatamab deruxtecan, given alone or with other treatments, to see if it is safe and can shrink tumors or lower P…

This study looks at the long-term safety of a drug called sotatercept for people with a specific type of high blood pressure in the lungs (Cpc-PH) caused by heart failure. About 130 adults who completed a prior study on this drug can join. The main goal is to see if sotatercept i…

This study tests a new drug, raludotatug deruxtecan, alone or with other treatments, for people with a fast-growing type of ovarian cancer that has returned after standard chemotherapy. The drug works like a smart bomb, attaching to cancer cells and delivering a toxic payload to …

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer than pembrolizumab alone. About 614 adults whose tumors have high PD-L1 levels (50% or more) and who…

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…

This study tests new experimental drugs combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the…

This study tests an HIV medicine called doravirine (alone or in a combination pill) in children aged 4 weeks to under 12 years who weigh less than 45 kg. The goal is to see how the drug works in their bodies, check for side effects, and ensure it controls the virus. About 84 chil…

This study follows about 3500 adults with solid tumors or blood cancers who are already taking or have taken pembrolizumab in earlier trials. Researchers want to see how safe and effective the drug is over a longer period. Participants may continue treatment or just be monitored,…

This study tests whether adding zanzalintinib to belzutifan helps people with advanced kidney cancer live longer or delay cancer growth compared to belzutifan alone. It is for adults whose cancer worsened after standard treatments. About 758 participants will receive either the d…

This study tests whether a new drug combination (nemtabrutinib plus venetoclax) works better than the current standard (venetoclax plus rituximab) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to at least one p…

This early-stage study tests a new drug called MK-1084, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 830 adults with…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer worsening. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive either…

This study tests a new medicine called MK-3120 for people with high-risk bladder cancer that hasn't spread into the bladder muscle. After standard surgery to remove the tumor, participants receive MK-3120 directly into the bladder. The main goals are to check the drug's safety an…

This study tests a new medicine called sacituzumab tirumotecan (sac-TMT) for people with advanced bladder cancer that got worse after earlier treatments. About 590 participants will receive either sac-TMT or standard chemotherapy. The main goal is to see if sac-TMT helps people l…

This study tests a new medicine called tulisokibart for people with rheumatoid arthritis (RA) who are already taking methotrexate. About 182 adults with active RA will receive either tulisokibart or a placebo to see if it reduces joint pain and swelling better than placebo. The g…

This study tests whether a once-weekly combination of two experimental drugs (islatravir and ulonivirine) works as well as a standard daily three-drug regimen (BIC/FTC/TAF) in adults newly diagnosed with HIV-1 who have never taken HIV medication. About 570 participants will be ra…

This study is for people with advanced bladder cancer that has spread. It tests adding new drugs to the standard treatment to see if they are safe and help shrink tumors. About 55 adults will take part. The goal is to find better ways to control the disease.

This study tests whether adding a new drug, enlicitide decanoate, to a standard cholesterol pill (rosuvastatin) lowers bad cholesterol more than a placebo plus the standard pill. About 975 adults with high cholesterol will take either the combination or a placebo for 8 weeks. The…

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The goal is …

This study tests a new targeted therapy, MK-1084, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and can shrink tumors. About 130 participants will receive the treatment, and research…

This study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help control metastatic castration-resistant prostate cancer (mCRPC), a type of advanced prostate cancer that no longer responds to hormone therapy. About 1,200 participants will rec…

This study tests a new drug called MK-3120 in 270 people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to check the drug's safety and whether people can tolerate it. Researchers will also see if the drug can shrink tumors.

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab after standard chemotherapy for advanced ovarian cancer. The goal is to see if it helps people live longer without their cancer growing back compared to current standard ca…

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who are already doing well on the drug bomedemstat. It aims to collect long-term safety information and see how well the drug continues to work. About 400 participants will be fo…

This study tests a new drug called tulisokibart in 1,200 people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut lining better than a placebo. Participants must have tried other treatments without success.

This study is for people with a certain type of lung cancer (stage II to IIIB) who have surgery after initial treatment but still have cancer cells remaining. It tests whether adding a new drug (MK-2870) to the standard immunotherapy (pembrolizumab) after surgery can help keep th…

This study tests whether adding belzutifan to fulvestrant works better than standard treatments for people with a common type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. About 120 adults will receive either the new combination or standard…

This study tests a medicine called vericiguat in children with heart failure caused by a weak left heart pump. About 342 kids from 1 month to 18 years old will take either vericiguat or a placebo for 16 weeks. The goal is to see if the medicine lowers a heart stress marker (NT-pr…

This study tests a new drug, bomedemstat, against the standard treatment hydroxyurea for people with essential thrombocythemia (ET) who have not yet received treatment to lower their blood cell counts. The goal is to see if bomedemstat is better at safely reducing platelet counts…

This study tests a new medicine called tulisokibart for people with a type of arthritis that causes pain and stiffness in the spine and hips. About 315 adults will receive either the study drug or a placebo to see if it improves symptoms like back pain and morning stiffness. The …

This study tests a new once-monthly pill (MK-8527) to prevent HIV-1 infection in women, comparing it to a standard daily PrEP pill. About 4,580 HIV-negative women who are sexually active will take either the monthly pill or a daily pill for up to 2 years. Researchers will check h…

This study tests whether taking MK-8527 once a month can prevent HIV-1 infection as well as the standard daily PrEP pill. About 4,390 participants who are HIV-negative and at risk (including cisgender men, transgender individuals, and nonbinary people) will be randomly assigned t…

This study tests the drug letermovir to prevent cytomegalovirus (CMV) in children and teens who have had a kidney transplant and weigh less than 40 kilograms. About 40 participants will receive the drug to see how it moves through their bodies and if it is safe. The goal is to fi…

This study tests whether suvorexant, a sleep medication, can help people with opioid use disorder who also have trouble sleeping. About 300 adults on stable opioid treatment will receive either the drug or a placebo. The goal is to see if the drug improves total sleep time and is…

This early-stage study tests a new medicine called MK-1403 in 52 adults with type 2 diabetes. The main goal is to check if the drug is safe and well-tolerated. Researchers will also measure how the drug moves through the body and whether it lowers a marker of inflammation (hsCRP)…

This early-stage study tests a new medicine called MK-1045 in 21 people with lupus or rheumatoid arthritis. The main goal is to see if the drug is safe and tolerable at different doses. Researchers will also measure how the drug moves through the body. This is a first step to fin…

This study looks at how two drugs interact in healthy adults. In Part 1, researchers measure how itraconazole changes the levels of MK-2828 in the body. In Part 2, they see if taking MK-2828 multiple times affects how the body handles a single dose of midazolam. The goal is to ga…

This early-stage study looks at how the drug MK-2828 is processed in people with different levels of kidney function, including those on dialysis. Researchers will compare these results to healthy volunteers. The goal is to understand if kidney disease changes how the drug works,…

This early-stage study in 16 healthy adults checks whether a new experimental HIV medicine, MK-4646, changes the levels of standard HIV drugs (BIC/FTC/TAF and dolutegravir) in the blood. The goal is to see if these combinations are safe and how the body processes them. Results wi…

This study looks at how two medicines, enlicitide and rosuvastatin, are absorbed by the body when taken as separate pills versus as a single combined tablet. About 60 healthy adults will participate to measure drug levels in the blood over time. The goal is to see if the combinat…

This study looks at how the body handles a single dose of the drug nemtabrutinib in people with moderate liver impairment compared to healthy volunteers. About 32 adults will take part to measure drug levels and check for side effects. The goal is to understand if liver problems …

This early-stage study in 14 healthy adults looks at how a single dose of MK-8527 changes the way the body processes methadone. Researchers will measure methadone levels in the blood over 24 hours. The study does not aim to treat any disease, only to gather safety and drug-intera…

This study looks at how the drug tulisokibart moves through the body when given by two different autoinjectors. About 330 healthy adults will receive a single injection to see if both devices deliver the drug the same way. Researchers will also check for side effects and how well…

This study looks at how the body processes a drug called MK-1084 when the liver is not working normally. Researchers will give a single dose to people with liver impairment and to healthy volunteers, then measure drug levels in the blood over time. The goal is to understand if li…